CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
Returns on capital
CytomX Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.5%
avg 1705.4%
ROIC
-20.5%
avg -22.7%
ROA
-11.5%
avg -16.6%
Analysis
ROA is currently the strongest return metric at -11.5% versus its period average of -16.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sean A. McCarthy DPHIL | Chairman & Chief Executive Officer | USD 1.43M | 59 | — | — |
Christopher W. Ogden | SVP, CFO & Secretary | USD 871.33K | 42 | — | — |
Marcia Belvin | Senior Vice President & Chief Scientific Officer | USD 634.83K | 59 | 300.76K | 0.19% |
Yu-Waye Chu | Senior VP & Chief Medical Officer | USD 496.94K | 58 | 189.45K | 0.12% |
Rachael Lester | Chief Business Officer & Senior Vice President | USD 241.52K | 48 | 20.00K | 0.01% |
Stephanie Robertson | Senior Vice President of Alliances & Program Leadership | — | — | — | — |
Alejandra Veronica Carvajal | Chief Legal Officer | — | 52 | — | — |
Danielle Olander-Moghadassian | Senior Vice President & Chief Human Resources Officer | — | — | — | — |
Dawn Benson | Senior Vice President of Quality & Product Manufacturing | — | — | — | — |
Leslie Robbins | Senior Vice President of Intellectual Property | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
5
$1.23M
Net Transaction Value
−$1.23M
Net selling
Most Active
Ogden Christopher
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 15, 26Jun 15, 2026 | Ogden Christopher Direct | Sell | $5K$4,953.20 |
| Mar 17, 26Mar 17, 2026 | Chu Yu-Waye Direct | Sell | $136.7K$136,675.02 |
| Mar 17, 26Mar 17, 2026 | McCarthy Sean A. Direct | Sell | $764.1K$764,137.89 |
| Mar 17, 26Mar 17, 2026 | BELVIN MARCIA Direct | Sell | $202.3K$202,273.12 |
| Mar 17, 26Mar 17, 2026 | Ogden Christopher Direct | Sell | $124.1K$124,111.63 |
Summary
Insiders reported 0 buys worth $0.00 and 5 sells worth $1.23M over the last 12 months. That adds up to net selling of $1.23M. Ogden Christopher was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +12.8% | +21.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +12.8% over three years. Forward estimates point to Revenue at +21.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does CytomX Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CTMX's management, answered from reported figures.
Who manages CTMX?
CytomX Therapeutics, Inc. (CTMX) lists 10 active executives. The top listed executive is Marcia Belvin, Senior Vice President & Chief Scientific Officer.
Are CTMX insiders buying or selling?
Recent insider activity shows net buying of $24.34M.
Continue the stock analysis
Jump to another research area for this company.